Back

Assessing the clinical utility of prescription EPA - What do the latest data suggest?

2 September 2019 (13:20 - 13:35)
Organised by:
Congress Presentation Part of: Reducing residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice Risk Factors and Prevention, Other ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor William Weintraub

Medstar Research Institute, Washington, DC (United States of America)

4 More presentations in this session

Presentation thumbnail
Welcome and introductions
Professor D. Bhatt (New York City, US)
Slides Video
Presentation thumbnail
Omega-3 fatty acids - Why they are not all the same?
Doctor P. Mason (Boston, US)
Slides Video
Presentation thumbnail
Omega-3s in the cardiology clinic - Practical implications and strategies to improve care.
Professor D. Bhatt (New York City, US)
Presentation thumbnail
Panel discussion and questions and answers session
Professor D. Bhatt (New York City, US)
Slides Video

Access the full session

Session thumbnail
Reducing residual risk for cardiovascular disease - Omega-3 fatty acids in cardiology practice

The Event

Event poster

ESC Congress 2019

2 September 2019 13:20 CET
You may be interested in
thumbnail
Congress Presentation
Cardiovascular risk reduction & hypertriglyceridemia: integrating the evidence
29 August 2025
thumbnail
Congress Presentation
HFpEF management comparison between HF-cardiologists, non-HF-cardiologists and other specialties: an international survey
13 May 2024
thumbnail
Congress Presentation
The clinical impact of polyunsaturated fatty acid on clinical outcomes in acute coronary syndrome with dyslipidemia: HIJ-PROPER sub-analysis
31 August 2019
thumbnail
Congress Presentation
Icosapent ethyl in clinical practice: the Spanish experience
29 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources